BIOXYTRAN, INC

OTC:BIXT

Pharmaceutical Preparations·NEEDHAM, MA

Summary Financials

Revenue

$246,495

FY 2017

Adj. EBITDA

-$3.8M

-1530.5% margin

FY 2024

Net Income

-$4.5M

-1814.4% margin

FY 2024

EPS (Diluted)

-$0.03

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$20,689

FY 2016

Total Debt

$48,000

FY 2024

Net Debt

$27,311

FY 2024

Enterprise Value

—

Debt / EBITDA

-0.0x

FY 2017

EV / EBITDA

—

Employees

—

Revenue

$246,495

FY 2017

Adj. EBITDA

-$3.8M

-1530.5% margin

FY 2024

Net Income

-$4.5M

-1814.4% margin

FY 2024

EPS (Diluted)

-$0.03

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$20,689

FY 2016

Total Debt

$48,000

FY 2024

Net Debt

$27,311

FY 2024

Enterprise Value

—

Debt / EBITDA

-0.0x

FY 2017

EV / EBITDA

—

Employees

—